A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus

• Status: ENROLLING_BY_INVITATION
• Trial end date: 2025-12-31

Summary

A randomized open, positive parallel controlled clinical study design was adopted. Participants were randomly assigned 1:1 according to inclusion criteria and exclusion criteria into two treatment regiments: Delu insulin liraglupeptide injection group and premixed insulin (or premixed insulin analogue). After fasting blood glucose was controlled at 7.5mmol /l in the morning, blood glucose was monitored by CGM (14d), and the Time in Range (3.9-10 mmol/l) was compared. Glycated albumin was measured and stool samples were taken before treatment and at 4 weeks.

• Phase: PHASE4

Details

• Lead Sponsor: Beijing Tsinghua Chang Gung Hospital
• Collaborators: Affiliated Hospital of Jiaxing University; Affiliated Hospital of Nantong University; Affiliated Zhoushan Hospital of Wenzhou Medical University; Chaohu Hospital of Anhui Medical University; Dongyang People's Hospital; Jinhua Municipal Central Hospital; Jinhua People's Hospital; Taizhou First People's Hospital; The Central Hospital of Lishui City; Wenzhou Central Hospital; Wenzhou People's Hospital; Wuhu City Second People's Hospital; Yiwu Central Hospital
• Treatments: insulin degludec